The world's first inhaled new crown vaccine for inhaled
"The vaccination process is like sucking a cup of milk tea, and the taste is a little sweet." On October 26, Shanghai launched inhaled novice vaccine to strengthen immunity. Some vaccinated people said this when they mentioned the feelings of vaccination.
Since the outbreak of the new crown epidemic in 2020, the recombinant novel coronavirus vaccine (adenovirus vector) developed by CanSino Biologics has become the first COVID-19 vaccine candidate in the country to enter the clinical research stage. While pushing the first COVID-19 vaccine (intolemnia injection) to clinical trials, CanSino Biologics scientists are also actively exploring the innovative vaccination process of the COVID-19 vaccine .
inhalation COVID-19 vaccine is based on the existing adenovirus vector intramuscular injection COVID-19 vaccine, and has innovatively changed the dosage method and dosage. It is understood that CanSino Biologics inhaled the new crown vaccine through the mouth and inhaled it into the lungs through the oral cavity, so that the atomized vaccine can pass through the respiratory tract and finally reach the lungs. While producing humoral immunity to and cellular immunity, it stimulates respiratory mucosal immunity.
Wang Jing said that the inhaled COVID-19 vaccine was not inhaled into the stomach, but entered the respiratory tract and lungs. Research shows that the transmission of respiratory droplets and close contact is still the main transmission path of the new coronavirus. Inhalation is done by inhalation and administration of the new coronavirus vaccine, the immune response is stimulated on the respiratory mucosa, the "first contact" of the body's contact with the virus, and a "invisible mask" is put on the inhaler, which is a powerful line of defense that is added in addition to humoral and cellular immunity.
Affected by the above news, vaccine concept stocks rose sharply on October 26, with CanSino hitting the daily limit, reaching 160.76 yuan as of the closing, and rose 20%. Deng Zhidong, general manager of Hainan Boao Medical Technology Co., Ltd., believes that it is necessary to strengthen vaccination. With the arrival of winter, the epidemic is on the rise, and a new round of feast in the vaccine industry has begun.
The growth of the original new crown vaccine slowed down
From research and development to innovative drug delivery methods, CanSino Biologics has been at the forefront. At the beginning of the COVID-19 outbreak, more than 20 domestic companies have carried out the research and development of COVID-19 vaccines, among which CanSino Biologics' COVID-19 vaccine was the first to enter clinical trials. In March 2020, the recombinant novel coronavirus vaccine (adenovirus vector) jointly developed by CanSino and the Institute of Bioengineering, Institute of Military Medicine, Academy of Military Sciences (hereinafter referred to as the "Academy of Military Sciences") was approved for clinical trials.
CanSino Biologics' "fast" depends on the company's mature adenovirus vector platform technology and the efforts of the team. The Ebola virus vaccine Ad5-EBOV, which was previously jointly developed by CanSino Biologics and the Academy of Military Sciences, uses the adenovirus vector platform technology. This vaccine has become an innovative recombinant vaccine product independently developed by my country and has completely independent intellectual property rights. In addition, in my country, CanSino Biologics is a special vaccine company, and its founder team has many years of background in drug research and development.
The novel coronavirus vaccine (adenovirus vector) is the first commercial product, which has brought returns to CanSino Biologics, which has continued to lose for many years. In February 2021, the National Medical Products Administration of conditionally approved the registration application for CanSino Biologics' recombinant novel coronavirus vaccine. With the launch of the first commercial product, CanSino Biologics turned losses into profits in 2021. According to financial report data, CanSino Biologics achieved operating income of 4.3 billion yuan throughout the year, an increase of 17174.82% year-on-year; and achieved net profit of 1.914 billion yuan, turning losses into profits year-on-year.
However, due to factors such as changes in vaccine product prices and slowing growth in global COVID-19 vaccination rate, CanSino Biologics' performance growth began to slow down. In the first half of 2022, CanSino Biologics achieved operating income of 630 million yuan, a year-on-year decrease of 69.45%; and achieved net profit of 12.238 million yuan, a year-on-year decrease of 98.69%. The semi-annual report said that it was mainly due to the slowdown in the global COVID-19 vaccination rate during the reporting period, the reduction in vaccine demand, the adjustment of vaccine product prices and the price of new crown vaccine-related inventory arrears that show signs of impairment.
What is the market space for inhalation vaccine
After the growth of intramuscular injection of the new crown vaccine will slow down, will inhalation of the new crown vaccine be a new opportunity for CanSino Biologics?
latest research shows that after 56 months of inoculating html inactivated vaccine html sequentially strengthened the inhalation of the new crown vaccine, the level of neutralizing antibodies against the Omickron mutant strain was 14 times that of the inactivated vaccine homologously strengthened and 6 times that of the sequential strengthened recombinant protein vaccine . The use of inhalation COVID-19 vaccine as the third or even the fourth intensification injection in the future will have much better effect than inactivated homologous enhancement.
Deng Zhidong believes that CanSino enhancement vaccine is convenient to use, has a wide range of applications, and does not require acupuncture when inhaling the oral inhalation method. It has significant effect on the Omickron mutant strain. It can also be used in a mixed manner, and its protective effect has been increased several times. It has strong market competitiveness and broad commercial prospects.
However, the inhaled COVID-19 vaccine is not used for basic immunization for the time being, and there are also requirements for the vaccinated population, which limits part of the imagination space. According to the relevant vaccination work guidelines, the subjects who have completed strengthening of immunization will not be further strengthened at this stage. In other words, if the population who have received three inactivated vaccines throughout the whole process cannot receive the inhalation of the new crown vaccine.
Currently, people aged 18 and above can make an appointment for inhalation of the new crown vaccine for inhalation after receiving two inactivated vaccines or one adenovirus vaccine for half a year. When vaccinating people aged 70 and above, they must be accompanied by their family members or volunteers.
It is reported that CanSino Biologics has plans to apply to relevant departments to include inhaled vaccines in the strengthening procedures for people aged 6-17, but a timetable has not been determined yet.
-END-
Beijing Business Daily reporter|Yao Qian
Picture source|Cansino Biologics official website
3
